Blueprint Medicines Corporation

Good morning. My name is Maxine and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines 3Q 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answers session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star followed by the number two. Please plan to limit yourself to one question. Thank you. Kristen Hodes of Blueprint Medicines, you may begin your conference.

Thank you, Operator. Good morning, everyone, and welcome to Blueprint Medicine's third quarter 2021 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at www.blueprintmedicines.com. Today on our call, Jeff Albers, our Chief Executive Officer, will discuss Blueprint Medicine's third quarter 2021 business highlights. Christy Rossi, our Chief Commercial Officer, will provide a commercial update. Fuad Nemuni, President of Research and Development, will review our recent clinical progress and highlight upcoming milestones across our growing pipeline. And Mike Lansdell, our Chief Financial Officer, will review our third quarter 2021 financial results. Becker Hughes, our Chief Medical Officer, is also on the call and will be available for Q&A. Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. Now, here's our CEO, Jeff Albers.

Thank you, Kristen, and good morning, everyone, and thanks for joining us today. In the third quarter, we made tremendous progress toward bringing our life-changing precision therapies to patients around the world. Today on our call, you'll hear about three areas of fundamental growth. The first is solid commercial performance anchored by Avakit's advanced systemic mastocytosis launch in the U.S. We're seeing broad demand from prescribers at both academic and community centers and across patients with different advanced SM subtypes. This momentum provides a foundation for continued leadership and growth for our SM franchise as we look to deliver top-line data from our pivotal, pioneered study of Avakit in non-advanced systemic mastocytosis in mid-2022 and accelerate development of BLU263, our next-generation kit inhibitor. The second area of growth is based around the continued execution and expansion of our R&D vision. With a robust pipeline of innovative, precision therapies advancing at all stages of development, As Fuad will describe, our next wave of clinical programs is progressing rapidly towards multiple proof of concept readouts. We've been encouraged by widespread interest in our Symphony trial of BLU945, and we're on track to initiate a phase one trial for BLU701 in the fourth quarter. Beyond our EGFR franchise, we continue to expect BLU222, our CDK2 inhibitor, and BLU852, our MAP4K1 inhibitor, to advance into clinical development next year. And a third area of strength is our current financial position, which, as Mike will describe in more detail, enables us to drive revenue growth across multiple domains, invest in a range of high-value R&D programs, and continue to build a world-class company with integrated global capabilities. For some time, we've talked about the promise of diverse revenue streams across the strategic pillars of our business. This diversity is now truly coming into view as we're able to increase our full-year revenue guidance based on activity throughout our portfolio, both independently driven and through our strategic collaborations. Combining our prolific scientific platform and commercial execution with the financial and organizational strength to bring in external assets, we're well positioned for Blueprint to be the leading driver of innovation in precision medicine for years to come. With that, I'll turn the call over to Christy to discuss our commercial efforts. Christy?